Study design
OAB
COMPOSUR is a 12-month, prospective, observational, real-world study (NCT05067478), with an optional 12-month extension to 24 months, in patients with OAB at 60 study sites in the US. Study sites are principally urology and urogynecology but with some family medicine practices across academic centers and community practices. Study visits occur at week 2 and again at 4- to 6-week, 12- to 20-week, and/or 24-to 36-week intervals from baseline depending on the treating provider’s usual practice for routine follow-up of patients with OAB (Fig. Schedule of baseline, follow-up, and final visits for enrolled patients. *Site staff virtual 2-week visit. This study is being conducted in compliance with the Declaration of Helsinki and with International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use/Good Clinical Practice guidelines. Investigators receive institutional review board (IRB) approval via central and/or local IRB, research ethics board approval, or independent ethics committee approval before the initiation of the study. All patients provide written informed consent.